Trial Profile
Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, Alone and in Combination With d4T and ddI as Compared to a Reference Combination Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Didanosine; Nelfinavir; Stavudine
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 08 Jun 2009 New trial record.